Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following…
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action…
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food…
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…
Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total…
LOS ANGELES, Aug. 6, 2024 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment…
NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life…
SAN FRANCISCO, Aug. 6, 2024 /PRNewswire/ -- Today, PicnicHealth, a company dedicated to simplifying observational research, announced the appointment of Jennifer…
Luminopia meets rigorous criteria set by Highmark's New Technology Advisory Committee (NTAC) and receives a positive coverage determination from the…
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…